Abstract: Novel thrombin/prothrombin protease/zymogen variants which have anticoagulation activity and methods of use thereof are disclosed.
Type:
Grant
Filed:
December 10, 2012
Date of Patent:
April 7, 2015
Assignee:
The United States of America National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), NIH Division of Extramural Inventions and Technology Resources (DEITR)
Inventors:
Sriram Krishnaswamy, Elsa P. Bianchini, Steven Orcutt
Abstract: The invention is in the field of skin hygiene, especially hand hygiene and/or hand soap compositions. It remains to be desired to prepare skin hygiene compositions having a high anti-microbial effect, even with a low dosage of anti-microbial essential oils. It is therefore an object of the invention to provide a skin hygiene composition, having good anti-microbial properties, at low levels of essential oil. Surprisingly it has been found that composition comprising a low amount of at least two essential oils and a polymer provides improved hygiene efficacy.
Abstract: The invention provides a composition for topical treatment of hair loss/alopecia including three natural, active ingredients, caffeine, saw palmetto berry extract, and epigallocatechin-3-gallate (EGCG). The invention also provides methods for using this composition to treat hair loss.
Type:
Grant
Filed:
February 9, 2012
Date of Patent:
March 24, 2015
Assignee:
Pilaris Labs LLC
Inventors:
Steven D. Shapiro, Michael T. Borenstein
Abstract: Because of the formation of disulfide bridges with mucus glycoproteins, the mucoadhesive properties of polymeric compounds can be significantly improved by the covalent attachment of thiol substructures to them. By the transformation of free thiol groups on such polymers in disulfides with mercaptonicotinamides or mercaptopyridoxins these thiol groups become comparatively more reactive resulting in significantly improved mucoadhesive properties. Furthermore, polymers exhibiting disulfide partial structures with mercaptonicotinamides or mercaptopyridoxins do not need to be protected against oxidation. In addition, they show comparatively higher permeation enhancing properties.
Abstract: The purpose of the present invention is to provide a press-coated orally-disintegrating tablet characterized by containing an inner core which has an excellent disintegratability in oral cavity and a suitable hardness as a whole tablet. The present invention relates to a press-coated orally-disintegrating tablet with an outer layer surrounding an inner core wherein the inner core has a thickness in the range of 10 to 90% per that of the whole tablet, and the outer layer comprises (a) microcrystalline cellulose, (b) an inorganic excipient, and (c) one or more particular ingredients selected from the group consisting of crospovidone, starches, low substituted hydroxypropylcellulose and carmellose.
Abstract: The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.
Abstract: The present invention relates generally to constructs and in particular genetic constructs comprising polynucleotide sequences capable of release in covalently closed, circular form from a larger nucleotide sequence such as, but not limited to, a genome of a eukaryotic cell. Preferably, once released, a polynucleotide sequence is reconstituted in a form which permits expression of the polynucleotide sequence. In one embodiment, the reconstituted polynucleotide sequence comprises a coding sequence with all or part of an extraneous nucleotide such as, but not limited to, an intronic sequence or other splice signal inserted therein. Expression and in particular transcription of the coding sequence involves splicing out the extraneous sequence. The release and circularization is generally in response to a stimulus such as a protein-mediated stimulus. More particularly, the protein is a viral or prokaryotic or eukaryotic derived protein or developmentally and/or tissue specific regulated protein.
Type:
Grant
Filed:
November 17, 2010
Date of Patent:
September 9, 2014
Assignee:
Queensland University of Technology
Inventors:
James Langham Dale, Benjamin Dugdale, Greg John Hafner, Scott Richard Hermann, Douglas Kenneth Becker, Robert Maxwell Harding, Srimek Chowpongpang
Abstract: An algal extract-based composition for oro-dental use is provided. This composition comprising a mixture of algae with at least Ascophyllum nodosum and Fucus spp. is characterized in that said mixture of algae has a proportion of Ascophyllum nodosum of at least 90% of the weight of the mixture and that the proportion of Fucus spp. is at most 10% of the weight of the mixture, and in that said extract is combined with a natural surfactant and/or with a zeolite or a mixture of zeolites. Uses of said composition, in particular for dental prevention and/or care, are also provided. Applications in the oro-dental field, both preventively and curatively.
Abstract: The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.
Type:
Grant
Filed:
July 25, 2013
Date of Patent:
August 12, 2014
Assignees:
Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
Inventors:
Jianjun Cheng, Omid C. Farokhzad, Robert S. Langer, Benjamin A. Teply, Stephen E. Zale
Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 6 (i.e., “?6-desaturase”). In particular, ?6-desaturase may be utilized, for example, in the conversion of linoleic acid to ?-linolenic acid and in the conversion of ?-linolenic acid stearidonic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.
Type:
Grant
Filed:
October 23, 2008
Date of Patent:
July 15, 2014
Assignee:
Abbott Laboratories
Inventors:
Pradip Mukerji, Yung-Sheng Huang, Amanda E. Leonard, Suzette L. Pereira, Jennifer M. Thurmond
Abstract: A natural nail polish composition made with all natural fruits and vegetable and only nontoxic ingredients. The natural nail polish composition comprises a lemon juice solution, a powdered form of fruits and/or vegetables, a powdered form of cane sugar, a nontoxic water soluble acrylic polymer, and a plurality of nontoxic colors. The plurality of colors comprises water soluble nontoxic pigments, nontoxic pigments, nontoxic mica, and nontoxic nail glitter. The natural nail polish composition is safe to use among young children because the composition is completely nontoxic. Since the composition is nontoxic, any kind of complications that may happen due to the chemicals in the traditional nail polish are completely prevented. The natural nail polish composition has a unique method of applying and removing the product. The natural nail polish composition can be mixed with the lacquer or shellac type products and creates an alternative nail polish composition.
Abstract: A recombinant replication competent retrovirus for gene deliver and gene therapy is provided. The recombinant retrovirus has a heterologous nucleic acid sequence, a sequence encoding a cell- or tissue-specific ligand or a sequence for transcriptional targeting, or a combination of both a cell- or tissue-specific ligand and a cell- or tissue-specific transcriptional targeting sequence.
Type:
Grant
Filed:
January 11, 2002
Date of Patent:
June 3, 2014
Assignee:
University of Southern California
Inventors:
Noriyuki Kasahara, Christopher Reid Logg, W. French Anderson
Abstract: The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.
Type:
Grant
Filed:
September 26, 2008
Date of Patent:
April 29, 2014
Assignees:
Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
Inventors:
Omid C. Farokhzad, Jianjun Cheng, Benjamin A. Teply, Robert S. Langer, Stephen E. Zale
Abstract: The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both ?134.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a pharmaceutical composition that includes the modified herpes simplex virus of the present invention and a pharmaceutically acceptable vehicle for in situ administration to tumor cells. Also provided in the present invention are methods for killing tumor cells in a subject and for immunizing a subject against an infectious disease, cancer, or an autoimmune disease that involve administering to a subject the modified avirulent, oncolytic herpes simplex virus of the present invention.
Abstract: A recombinant replication competent retrovirus for gene deliver and gene therapy is provided. The recombinant retrovirus has a heterologous nucleic acid sequence, a sequence encoding a cell- or tissue-specific ligand or a sequence for transcriptional targeting, or a combination of both a cell- or tissue-specific ligand and a cell- or tissue-specific transcriptional targeting sequence.
Type:
Grant
Filed:
November 7, 2011
Date of Patent:
February 18, 2014
Assignee:
University of Southern California
Inventors:
Noriyuki Kasahara, Christopher R. Logg, W. French Anderson
Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
Type:
Grant
Filed:
January 21, 2010
Date of Patent:
January 28, 2014
Assignees:
The Hospital for Sick Children, Centre for Addiction and Mental Health
Abstract: The invention relates methods and products for inducing mucosal immunity. In particular, the invention relates to the use of immunostimulatory oligonucleotides containing a CpG motif for inducing mucosal immunity. The CpG immunostimulatory oligonucleotides may be administered alone or in combination with antigen and/or with other adjuvants.
Abstract: The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.
Type:
Grant
Filed:
March 21, 2008
Date of Patent:
June 4, 2013
Assignee:
Berg Pharma LLC
Inventors:
John Patrick McCook, Indushekhar Persaud, Niven Rajin Narain
Abstract: A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in the subject. This invention further provides related articles of manufacture and methods.
Type:
Grant
Filed:
September 14, 2005
Date of Patent:
April 30, 2013
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
Richard B Robinson, Michael R Rosen, Ira S. Cohen, Peter R. Brink, Glenn Gaudette, Irina Potapova
Abstract: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
Type:
Grant
Filed:
September 20, 2011
Date of Patent:
April 30, 2013
Assignee:
Celator Pharmaceuticals, Inc.
Inventors:
Lawrence Mayer, Sharon Johnstone, Troy Harasym